Tirzepatide vs Retatrutide: An Honest Comparison

How tirzepatide and retatrutide differ in mechanism, potency and evidence — and how to decide which is right for your research.

Both compounds sit in the same aisle of the UK weight-management market, both are weekly injectables, and both are frequently compared. They are not interchangeable, and the differences that matter are receptor-level, not marketing-level. This guide compares the two on evidence grade, approval status, reported outcomes, tolerability signals, cost and legal position. Nothing here is medical advice; both compounds are discussed for research purposes only and are not for human or veterinary use.

The receptor difference is the whole story

Tirzepatide is a dual agonist: it engages GIP and GLP-1 receptors. Retatrutide is a triple agonist: GLP-1, GIP and glucagon (GCGR). The mechanistic argument for adding the third receptor is that glucagon activation raises energy expenditure and modulates hepatic glucose output, producing greater effect than dual agonism at comparable gastrointestinal tolerability in the populations studied.

That has practical consequences. The two compounds have overlapping but not identical tolerability profiles — retatrutide's glucagon arm adds a heart-rate signal that does not apply to tirzepatide — and they occupy different points on the evidence ladder. "GLP-1s are all the same" is a myth, and these two are the clearest proof of it.

Evidence grade and approval status

Tirzepatide sits at evidence grade A. It is approved for type 2 diabetes and for obesity (Mounjaro/Zepbound, Eli Lilly), with Phase 3 registration trials, a MASH programme (SURMOUNT-MASH) and a positive cardiovascular outcome trial (SURPASS-CVOT) behind it. SURMOUNT-1 reported −20.9% to −22.5% bodyweight at 72 weeks, dose-dependent.

Retatrutide sits at evidence grade B. Its Phase 3 programme (TRAILBLAZER and TRIUMPH) is complete, but approval is pending as of 2026 and the compound is not approved anywhere. Projected timelines put MHRA approval at late 2027 at the earliest, with mid-2028 more likely, and NICE appraisal in 2028–29.

In short: one is a licensed medicine with a decade of trial infrastructure behind it; the other is the strongest-evidenced unapproved compound in the category.

Reported outcomes compared

Where the numbers exist, they are reported trial results in trial populations — not predictions:

Tirzepatide: −20.9% to −22.5% bodyweight at 72 weeks (SURMOUNT-1), dose-dependent
Retatrutide: −28.7% at 12mg over 68 weeks (TRIUMPH-4, December 2025); 28.3% at 12mg over 80 weeks and 30.3% at 104 weeks (TRIUMPH-1, May 2026), with 45.3% of participants reaching at least 30% loss and 72% pre-diabetes reversal at 104 weeks

The directional read is that the triple agonist reports larger mean losses than the dual agonist at the studied doses. The caveat is that cross-trial comparison is not head-to-head evidence: different populations, durations and endpoints. Any supplier presenting the retatrutide figure directly against the tirzepatide figure as if it were a controlled comparison is overstating the case.

Safety and tolerability signals

Both compounds report the class-typical gastrointestinal profile: nausea and constipation are the most common events, with injection-site reactions also reported, and rare pancreatitis signals noted in the class literature. In tirzepatide's case the reported spectrum is described as similar to semaglutide's in comparison write-ups.

The distinguishing signal for retatrutide is dysesthesia — reported at 20.9% at 12mg in TRIUMPH-4 — plus increased resting heart rate, which is mechanistically consistent with glucagon receptor activity. Retatrutide's trial literature also notes rare cholelithiasis. Neither profile is "cleaner" than the other in any general sense; they are different profiles.

Cost and the UK market

Here the two diverge sharply. Around 80% of UK weight-loss-only users are on Mounjaro or tirzepatide, semaglutide is second, and retatrutide is the rising third. Mounjaro 15mg list price has risen to roughly £330 per month, and an Oxford review found around 50% of GLP-1 users stop within 12 months with cost the leading reason at about 38.7%.

The emerging buying metric is cost per percentage of bodyweight lost. One UK cost guide estimates retatrutide at roughly £5–7 per percent against roughly £25–30 per percent for Wegovy; treat those as the guide's estimates rather than clinical data. The general point stands: tirzepatide is the established default with pharmacy and telehealth pricing behind it, while retatrutide is the higher-evidence-per-pound challenger inside a finite pre-approval window.

How to choose which to study

Map the choice to the question being asked rather than to the headline number:

If the research question requires a compound with a full regulatory dossier, published CVOT data and an approved indication, tirzepatide is the appropriate reference.
If the question concerns triple agonism, glucagon-mediated energy expenditure, or the newer trial data, retatrutide is the compound under study.
If the question is about cost per unit of reported effect in the current UK market, that is a market question rather than a pharmacology one — and the pre-approval window for retatrutide is a time-limited variable.

Is it legal in the UK?

Neither tirzepatide nor retatrutide is a controlled substance under the Misuse of Drugs Act 1971. The MHRA treats peptides sold for human use as unlicensed medicines and focuses enforcement on sellers, suppliers and clinics rather than individual importers. Personal importation of small quantities is a grey zone — tolerated in practice, not explicitly legal — and confiscation rather than prosecution is the typical outcome of a seizure. UK customs enforcement on peptides has been assessed as the least aggressive of the five major markets.

Both compounds are specifically in scope for enforcement attention. The MHRA has said the "for research purposes only" label is a soft shield it may disregard where used to evade medicines regulation, and it treats GLP-1-class compounds as the highest-risk "research" category. A February 2026 raid in Lincolnshire seized around 2,000 doses including retatrutide and tirzepatide; an October 2025 Northampton seizure took 2,000-plus pens; and in April 2026 the MHRA opened an investigation into UK peptide clinics over health claims. UK-held stock removes customs and import-VAT exposure but does not remove compliance obligations.

Where this fits at Peptide Supply Guy

Both compound families are stocked in the UK with a certificate of analysis per batch:

Tirzepatide 10mg — £16.15 per vial (card price); Tirzepatide 30mg — £28.90 per vial (card price); Tirzepatide 60mg — £56.10 per vial (card price)
Retatrutide 10mg — £25.50 per vial (card price); Retatrutide 20mg — £39.95 per vial (card price); Retatrutide 60mg — £120.70 per vial (card price)

If your comparison work covers the dual-versus-triple question directly, the smaller tirzepatide and retatrutide vials are the matched starting points. All compounds are supplied strictly for research purposes only, with no dosing or medical guidance provided.